Last reviewed · How we verify
Fosamprenavir/ritonavir
Fosamprenavir is a protease inhibitor that blocks HIV protease, preventing viral replication, while ritonavir acts as a pharmacokinetic booster to increase fosamprenavir levels.
Fosamprenavir is a protease inhibitor that blocks HIV protease, preventing viral replication, while ritonavir acts as a pharmacokinetic booster to increase fosamprenavir levels. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | Fosamprenavir/ritonavir |
|---|---|
| Also known as | Lexiva/Norvir |
| Sponsor | ViiV Healthcare |
| Drug class | HIV protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Fosamprenavir is a prodrug that is converted to amprenavir, which inhibits HIV protease and prevents the cleavage of viral polyproteins necessary for infectious particle maturation. Ritonavir is a potent CYP3A4 inhibitor that dramatically increases fosamprenavir plasma concentrations, allowing for lower and less frequent dosing while maintaining therapeutic efficacy.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Diarrhea
- Nausea
- Rash
- Headache
- Vomiting
- Hyperglycemia
- Lipid abnormalities
Key clinical trials
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects (PHASE2)
- Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People (NA)
- Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV (PHASE2)
- IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents
- Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA) (PHASE1)
- Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fosamprenavir/ritonavir CI brief — competitive landscape report
- Fosamprenavir/ritonavir updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI